Patents & Publications

product name

Patented Equipment

At IBT, we believe innovation thrives through collaboration. Our lab outsourcing and strategic partnerships allow research institutions, biotech firms, and clinical teams to extend their capabilities without expanding their infrastructure. Whether you’re looking to fast-track development or scale your testing, our team integrates seamlessly with yours—bringing decades of experience, cutting-edge technology, and a flexible engagement model to every project.

product name

Research Lab Outsourcing and Partnerships

At IBT, we believe innovation thrives through collaboration. Our lab outsourcing and strategic partnerships allow research institutions, biotech firms, and clinical teams to extend their capabilities without expanding their infrastructure. Whether you’re looking to fast-track development or scale your testing, our team integrates seamlessly with yours—bringing decades of experience, cutting-edge technology, and a flexible engagement model to every project.

All Projects

product name

Bioartificial Renal Epithelial Cell System (BRECS)

Bioartificial Renal Epithelial Cell System (BRECS) Using adult renal progenitor cells, isolated from human transplant organ discards, IBT has developed a bioartificial kidney to be worn outside of the body. This device has the potential to be used in both acute and chronic therapeutic applications. IBT plans to advance the product from pre-clinical trials to human clinical trials within 3-5 years.

product name

Bioartificial Pancreatic Islet Cell System (BPICS)

An innovative approach to the treatment of insulin-dependent diabetes, the BPICS would use pancreatic islet cells to regulate blood sugar. Dr. Humes, Founder and President, says “[the BPICS] will control blood sugar via the natural biologic processes in which insulin production is regulated on a minute-to-minute basis in response to changes in blood glucose levels.”

product name

Selective Cytopheretic Device (SCD)

The selective cytopheretic device (SCD) is a device used to treat acute inflammatory conditions in patients, which are life-threatening. The SCD sequesters and deactivates cells associated with inflammation, such as leukocytes and platelets, and reduces their inflammatory activity.

product name

Enhanced Propagation (EP) of Cells

This cell isolation and expansion method allows for the propagation, or growth, of large volumes of cells for use in biotherapeutic devices. EP allows for expansion of cells from 1 gram of tissue such that over 2,000 biomedical devices can be generated, each containing 108 cells.

Search Our Publications & Patents Titles

List of Active Patents

Sub Headline Goes Here

Cartridge and method for increasing myocardial function

TSeaStar Medical Inc.,Denver, CO 80216,US,101972830

Publication Number: EP4194024A1

Status: Pending

Expiration Date1: N/A

Expiration Date: N/A

Selective cytopheresis devices and related methods thereof

The Regents of the University of Michigan,Ann Arbor,MI,US | CytoPherx Inc.,Ann Arbor,MI,US

Publication Number: US8251941B2

Status: Active

Expiration Date1: Adjusted Expiration: 2031-04-22

Expiration Date: April, 2031

Selective cytopheresis devices and related methods thereof

The Regents of the University of Michigan,Ann Arbor,MI,US | CytoPherx Inc.,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US8409126B2

Status: Active

Expiration Date1: Adjusted Expiration: 2029-06-23

Expiration Date: June, 2029

Selective cytopheresis devices and related methods thereof

The Regents of the University of Michigan,Ann Arbor,MI,US | CytoPherx Inc.,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US8425445B2

Status: Active

Expiration Date1: Adjusted Expiration: 2029-05-07

Expiration Date: May, 2029

Selective cytopheresis devices and related methods

The Regents of the University of Michigan,Ann Arbor,MI,US | CytoPherx Inc.,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US8425446B2

Status: Active

Expiration Date1: Adjusted Expiration: 2029-07-25

Expiration Date: July, 2029

Selective cytopheresis devices and related methods thereof

The Regents of the University of Michigan,Ann Arbor,MI,US | CytoPherx Inc.,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US8425447B2

Status: Active

Expiration Date1: Anticipated Expiration: 2028-08-29

Expiration Date: August, 2028

Selective cytopheresis devices and related methods thereof

The Regents of the University of Michigan,Ann Arbor,MI,US | CytoPherx Inc.,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US8430832B2

Status: Active

Expiration Date1: Adjusted Expiration: 2029-08-08

Expiration Date: August, 2029

Selective cytopheresis devices and related methods thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN,Ann Arbor,MI,US | CYTOPHERX INC.,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US9128093B2

Status: Active

Expiration Date1: Adjusted Expiration: 2029-10-09

Expiration Date: October, 2029

Selective cytopheresis devices and related methods thereof

CYTOPHERX INC.,Ann Arbor,MI,US | THE REGENTS OF THE UNIVERSITY OF MICHIGAN,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US9341626B2

Status: Active

Expiration Date1: Adjusted Expiration: 2031-01-07

Expiration Date: January, 2031

Selective cytopheresis devices and related methods thereof

CYTOPHERX INC.,Ann Arbor,MI,US | THE REGENTS OF THE UNIVERSITY OF MICHIGAN,Ann Arbor,MI,US | Humes H. David,Ann Arbor,MI,US | Buffington Deborah,Ann Arbor,MI,US

Publication Number: US9498566B2

Status: Active

Expiration Date1: Adjusted Expiration: 2029-10-22

Expiration Date: October, 2029

Selective cytopheresis devices

SeaStar Medical Inc.,Denver, CO 80216,US,101972830 | The Regents of the University of Michigan,Ann Arbor, MI 48109-2590,US,101993185

Publication Number: EP3789056B1

Status: Active

Expiration Date1: Anticipated Expiration: 2028-08-29

Expiration Date: August, 2028

Cytopheresis cartridges and use thereof

SeaStar Medical Inc.,Cardiff by the Sea, CA 92007,US,101851369

Publication Number: EP2627369B1

Status: Active

Expiration Date1: Anticipated Expiration: 2031-10-14

Expiration Date: October, 2031

Cytopheresis cartridges and use thereof

SeaStar Medical Inc.,Denver,CO,US | SeaStar Medical Inc.,Cardiff-By-The-Sea,CA,US

Publication Number: US11118162B2

Status: Active

Expiration Date1: Adjusted Expiration: 2032-09-28

Expiration Date: September, 2032

Cytopheresis cartridges and use thereof

SeaStar Medical Inc.,Denver,CO,US

Publication Number: US11866730B2

Status: Active

Expiration Date1: Adjusted Expiration: 2032-09-28

Expiration Date: September, 2032

Cytopheresis cartridges and use thereof

SeaStar Medical Inc.,Denver,CO,US

Publication Number: US11866730B2

Status: Active

Expiration Date1: Adjusted Expiration: 2032-02-14

Expiration Date: February, 2032

Cartridge and method for increasing myocardial function

SeaStar Medical Inc.,Denver,CO,US | SeaStar Medical Inc.,Cardiff-By-The-Sea,CA,US

Publication Number: US10722637B2

Status: Active

Expiration Date1: Anticipated Expiration: 2032-10-11

Expiration Date: October, 2032

Cartridge and method for increasing myocardial function

SeaStar Medical Inc.,Denver,CO,US

Publication Number: US11439739B2

Status: Active

Expiration Date1: Anticipated Expiration: 2032-10-10

Expiration Date: October, 2032

Cartridge and method for increasing myocardial function

SeaStar Medical Inc.,Cardiff-by-the-Sea,CA,US

Publication Number: US10695482B2

Status: Active

Expiration Date1: Anticipated Expiration: 2032-10-10

Expiration Date: October, 2032

Extracorporeal cell-based therapeutic device and delivery system

Innovative BioTherapies Inc.,Ann Arbor,MI,US

Publication Number: US8048419B2

Status: Active

Expiration Date1: Adjusted Expiration: 4/19/2028

Expiration Date: April, 2028

List of Patents

Sub Headline Goes Here

Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules

The University of Michigan,Ann Arbor,MI

Publication Number: US6410320B1

Status: Expired - Fee related

Expiration Date: N/A

Implantable device and use therefor

Nephros Therapeutics Inc.,Ann Arbor,MI

Publication Number: US6572605B1

Status: Expired - Fee related

Expiration Date: N/A

Implantable device and use therefor

Nephros Therapeutics Inc.,Lincoln,RI

Publication Number: US6716208B2

Status: Expired - Fee related

Expiration Date: N/A

Bioartificial filtration device for filtering blood to mimic kidney function

The Regents of the University of Michigan,Ann Arbor,MI,US

Publication Number: US6942879B2

Status: Expired - Fee related

Expiration Date: N/A

Extracorporeal fluid circuit and related methods

Nephros Therapeutics Inc.,Lincoln,RI,US | The Regents of the University of Michigan,Ann Arbor,MI,US

Publication Number: US6913588B2

Status: Expired - Fee related

Expiration Date: N/A

Device for maintaining vascularization near an implant

RenaMed Biologics Inc.,Lincoln,RI,US

Publication Number: US7332330B2

Status: Expired - Fee related

Expiration Date: N/A

Filtration devices and related methods thereof

The Regents of the University of Michigan,Ann Arbor,MI,US

Publication Number: US7874998B2

Status: Expired - Fee Related

Expiration Date: March, 2029

Method and formulations for the therapy of acute renal failure

The Regents of the University of Michigan,Ann Arbor,MI,US

Publication Number: US5360790A

Status: Expired - Lifetime

Expiration Date: N/A

Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules

University of Michigan,Ann Arbor,MI,US

Publication Number: US5429938A

Status: Expired - Lifetime

Expiration Date: N/A

Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo

The Regents of The University of Michigan,Ann Arbor,MI,US

Publication Number: US5549674A

Status: Expired - Lifetime

Expiration Date: N/A

Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules

The University of Michigan,Ann Arbor,MI,US

Publication Number: US6060270A

Status: Expired - Lifetime

Expiration Date: N/A

Method and compositions of a bioartificial kidney suitable for use in vivo or ex vivo

The University of Michigan,Ann Arbor,MI,US

Publication Number: US5686289A

Status: Expired - Lifetime

Expiration Date: N/A

Implantable device and use therefor

Nephros Therapeutics Inc.,Ann Arbor,MI,US

Publication Number: US5704910A

Status: Expired - Lifetime

Expiration Date: N/A

Implantable device and uses therefor

Nephros Therapeutics Inc.,Ann Arbor,MI,US

Publication Number: US5911704A

Status: Expired - Lifetime

Expiration Date: N/A

Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo

The Regents of the University of Michigan,Ann Arbor,MI,US

Publication Number: US6150164A

Status: Expired - Lifetime

Expiration Date: N/A

Extracorporeal fluid circuit and related methods

The Regents of the University of Michigan,Ann Arbor,MI | Nephros Therapeutics Inc.,Ann Arbor,MI

Publication Number: US6561997B1

Status: Expired - Lifetime

Expiration Date: N/A

Method of treating systemic inflammatory response syndrome

The Regents of the University of Michigan,Ann Arbor,MI

Publication Number: US6653131B2

Status: Expired - Lifetime

Expiration Date: N/A

Method of modulating inflammatory response

The Regents of the University of Michigan,Ann Harbor,MI,US

Publication Number: US7442546B2

Status: Expired - Lifetime

Expiration Date: N/A

Ultrafiltration membrane, device, bioartificial organ, and methods

Regents of the University of Michigan,Ann Arbor,MI,US | Cleveland Clinic Foundation,Cleveland,OH,US

Publication Number: US7048856B2

Status: Expired - Lifetime

Expiration Date: N/A

Ultrafiltration membrane, device, bioartificial organ, and methods

The Regents of the University of Michigan,Ann Arbor,MI,US | The Cleveland Clinic Foundation,Cleveland,OH,US

Publication Number: US7540963B2

Status: Expired - Lifetime

Expiration Date: N/A

Medical device connector

CytoPherx Inc,Ann Arbor,MI,US

Publication Number: USD630319S1

Status: Expired - Lifetime

Expiration Date: N/A

Medical device connector

CytoPherx Inc,Ann Arbor,MI,US

Publication Number: USD629893S1

Status: Expired - Lifetime

Expiration Date: N/A

Method for kidney tubulogenesis

THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Publication Number: WO1993017696

Status: N/A

Expiration Date: N/A

Method and compositions of a bioartificial kidney suitable for use in vivo or ex vivo

THE REGENTS OF THE UNIVERSITY OF MICHIGAN US,US

Publication Number: WO1995011048

Status: N/A

Expiration Date: N/A

A device for delivering a preselected molecule into the system ciculation

NEPHROS THERAPEUTICS INC.

Publication Number: WO1996039098

Status: N/A

Expiration Date: N/A

Extracorporeal circuit and related methods

NEPHROS THERAPEUTICS INC,US | UNIV MICHIGAN,US

Publication Number: WO2000064510

Status: N/A

Expiration Date: N/A

Intravascular drup delivery device and use therefor

NEPHROS THERAPEUTICS INC.,US

Publication Number: WO2002055136

Status: N/A

Expiration Date: N/A

Method of treating systemic inflammatory response syndrome

THE REGENTS OF THE UNIVERSITY OF MICHIGAN,US

Publication Number: WO2003020104

Status: N/A

Expiration Date: N/A

Method of modulating inflammatory response

HUMES David H.,US

Publication Number: WO2003077840

Status: N/A

Expiration Date: N/A

Ultrafiltration membrane, device, bioartificial organ, and methods

UNIV MICHIGAN,US | FISSELL WILLIAM H IV,US | HUMES DAVID H,US | ROY SHEVO,US

Publication Number: WO2004024300

Status: N/A

Expiration Date: N/A

Methodds of treating cardiorenal syndrome and hepatorenal syndrome

THE REGENTS OF THE UNIVERSITY OF MICHIGAN,US

Publication Number: WO2006138537

Status: N/A

Expiration Date: N/A

An extracorporeal cell-based therapeutic device and delivery system

INNOVATIVE BIO THERAPIES,US | HUMES H. David,US

Publication Number: WO2007092735

Status: N/A

Expiration Date: N/A

Selective cytopheresis devices and related methods thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN,US | HUMES H. David,US | BUFFINGTON Deborah,US

Publication Number: WO2009029801

Status: N/A

Expiration Date: N/A

An extracorporeal cell-based therapeutic device and delivery system

INNOVATIVE BIOTHERAPIES INC.,US | HUMES H. David,US | BUFFINGTON Deborah,US | HAGEMAN Gretchen,US

Publication Number: WO2010019643

Status: N/A

Expiration Date: N/A

Cytopheresis cartridges and use thereof

CYTOPHERX INC.,US | HUMES H. David,US | BUFFINGTON Deborah,US | PINO Christopher J.,US

Publication Number: WO2012051595

Status: N/A

Expiration Date: N/A

Cartridge and method for increasing myocardial function

HUMES H. David,US | BUFFINGTON Deborah A.,US

Publication Number: WO2013106109

Status: N/A

Expiration Date: N/A

Cartridge and method for increasing myocardial function

CYTOPHERX INC.,US

Publication Number: WO2013106108

Status: N/A

Expiration Date: N/A

All Publications

product name

Bioartificial Renal Epithelial Cell System (BRECS)

Bioartificial Renal Epithelial Cell System (BRECS) Using adult renal progenitor cells, isolated from human transplant organ discards, IBT has developed a bioartificial kidney to be worn outside of the body. This device has the potential to be used in both acute and chronic therapeutic applications. IBT plans to advance the product from pre-clinical trials to human clinical trials within 3-5 years.

Publications

Sub Headline Goes Here

A Selective Cytopheretic Inhibitory Device to Treat the Immunological Dysregulation of Acute and Chronic Renal Failure

A Biomimetic Membrane Device That Modulates the Excessive Inflammatory Response to Sepsis

The Effect of the Selective Cytopheretic Device on Acute Kidney Injury Outcomes in the Intensive Care Unit: A Multicenter Pilot Study

A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury

Use of the Selective Cytopheretic Device in Critically Ill Children

Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients

Rationale and Design of NEUTRALIZE-AKI: A Multicenter, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury Requiring Continuous Kidney Replacement Therapy

Hemolytic Uremic Syndrome-Induced Acute Kidney Injury Treated via Immunomodulation with the Selective Cytopheretic Device: Cases of STEC-HUS Treated with Immunomodulation via SCD CRRT Filter

Extracorporeal Immunomodulation Therapy in Acute Chronic Liver Failure With Multiorgan Failure: First in Human Use

Safety Summary of the Selective Cytopheretic Device: A Review of Safety Data Across Multiple Clinical Trials in ICU Patients With Acute Kidney Injury and Multiple Organ Failure

Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human

Selective Cytopheretic Device Use in Continuous Kidney Replacement Therapy in Children: A Cohort Study With a Historical Comparator

New opportunity for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation

Increasing Eligibility to Transplant Through the Selective Cytopheretic Device: A Review of Case Reports Across Multiple Clinical Conditions

Immunomodulatory effects of a cell processing device to ameliorate dysregulated hyperinflammatory disease states

The Impact of the Selective Cytopheretic Device on Neutrophil-to-Lymphocyte Ratios and Hematological Parameters in Acute Kidney Injury: A Pooled Analysis

Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury

Current Experience Using the Selective Cytopheretic Device for Continuous Immunomodulation in Acute Kidney Injury and Multiorgan Failure

Immune Cell Therapy: Promising Approach to Reduce Chronic Kidney Disease Risk in Heart Failure

Selective Cytopheretic Device (QUELimmune) A Leukocyte Processing, Immunomodulatory Device

Management dilemma in choosing evolving treatments in neutropenic septic shock